Publications by authors named "Jaap Reijneveld"
Article Synopsis
- - The study focused on developing and preliminarily validating the Scale for Objective Diagnostic Components of Paroxysmal Events (STAMP), which categorizes seizure-like events, including epileptic seizures, functional seizures, and syncope.
- - Researchers analyzed data from 200 patients referred to a Dutch epilepsy center, noting that 131 had epileptic seizures, 17 had functional seizures, and findings indicated significant diagnostic improvements through various event recordings during follow-up.
- - The findings suggest that regular monitoring through STAMP can enhance diagnostic accuracy, although further validation of the scale is needed to fully establish its effectiveness.
Background: Standard treatment for patients with newly diagnosed glioblastoma includes surgery, radiotherapy (RT), and temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). The proteasome has long been considered a promising therapeutic target because of its role as a central biological hub in tumor cells. Marizomib is a novel pan-proteasome inhibitor that crosses the blood-brain barrier.
View Article and Find Full Text PDFThis narrative review provides an overview of the current knowledge on health-related quality of life (HRQOL), a relevant clinical outcome in patients with epilepsy. It shows that the most important factor determining HRQOL in this patient group is seizure frequency. In particular, seizure-freedom is associated with better HRQOL scores.
View Article and Find Full Text PDFArticle Synopsis
- Glioma is linked to increased brain activity around tumors, which contributes to faster disease progression and changes in how different brain regions communicate, affecting symptoms.
- The study analyzed brain activity and connectivity in 84 glioma patients and compared it to 61 healthy individuals, focusing on the power spectrum and network connectivity measures like clustering coefficient and eigenvector centrality.
- Findings showed that while tumor-related activity was high in patients, it corresponded to low connectivity in their brain networks, suggesting a complicated relationship between tumor activity and brain function, which could impact how the disease and its symptoms develop.
Background: In an international randomised controlled phase II study of temozolomide (TMZ) versus TMZ in combination with bevacizumab (BEV) in locally diagnosed non-1p/19q co-deleted World Health Organization grade 2 or 3 gliomas with a first and contrast-enhancing recurrence after initial radiotherapy, and overall survival at 12 months was not significantly different (61% in the TMZ arm and 55% in the TMZ + BEV arm).
Objectives: Health-related quality of life (HRQoL) was a key secondary end-point in this trial, and the main objective of this study was to determine the impact of the addition of BEV to TMZ on HRQoL.
Methods: HRQoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30 (version 3) and QLQ-BN20 at baseline, and then every 12 weeks until disease progression.
Background: Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined.
View Article and Find Full Text PDFArticle Synopsis
- Early guidelines set a minimally important difference (MID) of ≥10 points for the EORTC QLQ-C30, but evidence suggests that MIDs vary based on scale, type of cancer, and other factors, questioning the validity of a universal standard.
- This study analyzed data from 21 EORTC Phase III trials involving 13,015 patients across nine different cancer types to identify pattern differences in MIDs for within- and between-group changes over time.
- Results showed that anchor-based MIDs typically ranged from 5 to 10 points, with notable variations based on scale and cancer type, highlighting the need for researchers to consider specific contexts rather than relying on a one-size-fits-all MID approach.
Patient-reported outcomes (PROs) are increasingly used in single-arm cancer studies. We reviewed 60 papers published between 2018 and 2021 of single-arm studies of cancer treatment with PRO data for current practice on design, analysis, reporting, and interpretation. We further examined the studies' handling of potential bias and how they informed decision making.
View Article and Find Full Text PDFMany patients with glioma, primary brain tumors, suffer from poorly understood executive functioning deficits before and/or after tumor resection. We aimed to test whether frontoparietal network centrality of multilayer networks, allowing for integration across multiple frequencies, relates to and predicts executive functioning in glioma. Patients with glioma (n = 37) underwent resting-state magnetoencephalography and neuropsychological tests assessing word fluency, inhibition, and set shifting before (T1) and one year after tumor resection (T2).
View Article and Find Full Text PDFBackground: Patients' reduced awareness of neurocognitive functioning (NCF) may negatively affect the reliability of patient-reported outcomes (PROs) and clinical decision-making. This study evaluated cognitive awareness, defined as the association between NCF and neurocognitive complaints, over the disease course of patients with recurrent high-grade glioma (HGG).
Methods: We assessed NCF using the EORTC core clinical trial battery and neurocognitive complaints using the Medical Outcome Study questionnaire.
The use of item libraries for patient-reported outcome (PRO) measurement in oncology allows for the customisation of PRO assessment to measure key health-related quality of life concepts of relevance to the target population and intervention. However, no high-level recommendations exist to guide users on the design and implementation of these customised PRO measures (item lists) across different PRO measurement systems. To address this issue, a working group was set up, including international stakeholders (academic, independent, industry, health technology assessment, regulatory, and patient advocacy), with the goal of creating recommendations for the use of item libraries in oncology trials.
View Article and Find Full Text PDFBackground: The feasibility of implementing an advance care planning (ACP) program in daily clinical practice for glioblastoma patients is unknown. We aimed to evaluate a previously developed disease-specific ACP program, including the optimal timing of initiation and the impact of the program on several patient-, proxy-, and care-related outcomes.
Methods: The content and design of the ACP program were evaluated, and outcomes including health-related quality of life (HRQoL), anxiety and depression, and satisfaction with care were measured every 3 months over 15 months.
Article Synopsis
- Gliomas tend to appear more frequently in brain regions with naturally higher intrinsic activity, as shown by increased spiking activity leading to faster tumor growth in animal studies.
- The study involved 413 patients and analyzed brain activity through resting-state magnetoencephalography, focusing on parameters like broadband power and aperiodic components, which relate to neuronal function.
- Findings indicate that gliomas are correlated with higher intrinsic brain activity in certain regions, and this activity at specific tumor locations varies based on tumor and patient characteristics.
Article Synopsis
- Early detection of tumors in cancer patients leads to better treatment outcomes for less advanced cancers.
- Tumor-educated platelets (TEPs) can be used for cancer detection via RNA-based blood tests, identifying 18 different cancer types with high accuracy.
- The thromboSeq test showed 99% specificity in asymptomatic controls, accurately detecting two-thirds of cancers in advanced stages, and helped determine the origin of tumors in over 80% of cases.
Purpose: The rate of missing data on patient-reported health-related quality of life (HRQOL) in brain tumor clinical trials is particularly high over time. One solution to this issue is the use of proxy (i.e.
View Article and Find Full Text PDFBackground: While patients with diffuse low-grade glioma (LGG) often survive for years, there is a risk of tumor progression which may impact patients' long-term health-related quality of life (HRQOL) and neurocognitive functioning (NCF). We present a follow-up of LGG patients and their informal caregivers (T3) who took part in our previous HRQOL investigations (T1, M = 7 and T2 M = 13 years after diagnosis).
Methods: Participants completed HRQOL (short form-36 health survey [SF-36]; EORTC-BN20), fatigue (Checklist Individual Strength [CIS]), and depression (Center for Epidemiological Studies-Depression [CES-D]) questionnaires and underwent NCF assessments.
Background: In patients with recurrent glioblastoma, corticosteroids are frequently used to mitigate intracranial pressure and to improve patient neurological functioning. To date, in these patients, no systematic studies have been performed to assess neurocognitive functioning (NCF) in relation to corticosteroid treatment.
Methods: Using baseline data (ie, prior to randomization) of European Organization for Research and Treatment of Cancer (EORTC) trial 26101, we performed regression analysis to assess the predictive value of corticosteroid intake on performance of the EORTC brain tumor clinical trial NCF test battery.
Article Synopsis
- * A study with 81 brain tumor patients and their proxies found that proxies often reported more problems than patients, especially in cases where the patient's cognitive function was impaired.
- * The findings suggest that patients with neurocognitive deficits may not fully recognize their own limitations in daily activities, highlighting the need for combining patient self-reports with proxy assessments for a more accurate picture.
Introduction: The European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) measures 15 health-related quality of life (HRQoL) scales relevant to the disease and treatment of patients with cancer. A study by Martinelli (2011) demonstrated that these scales could be grouped into three main clusters: physical, psychological and gastrointestinal. This study aims to validate Martinelli's findings in an independent dataset and evaluate whether these clusters are consistent across cancer types and patient characteristics.
View Article and Find Full Text PDFPurpose: Cancer-related neurocognitive impairment and poor sleep are prevalent in cancer survivors and have a negative impact on their quality of life. This systematic review studies the association between sleep disturbance and neurocognitive functioning, as well as the potential positive effects of sleep interventions on neurocognitive functioning in cancer survivors. In addition, we aimed at determining the potential positive effects of sleep interventions on neurocognitive functioning in this population.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on maintaining health-related quality of life (HRQoL) for glioma patients during their progression-free survival (PFS) period.
- Analysis of HRQoL data from past trials shows that 47% of patients experienced deterioration in HRQoL despite not progressing in the disease, with only poor performance status being a significant factor linked to this decline.
- The findings highlight the need for regular monitoring of patients' well-being throughout their treatment to identify and address HRQoL issues early on.
Purpose: Despite recent advances in the molecular characterization of gliomas, it remains unclear which patients benefit most from which second-line treatments. The TAVAREC trial was a randomized, open-label phase II trial assessing the benefit of the addition of the angiogenesis inhibitor bevacizumab to treatment with temozolomide in patients with a first enhancing recurrence of World Health Organization grade 2 or 3 glioma without 1p/19q codeletion. We evaluated the prognostic significance of genome-wide DNA methylation profiles and copy-number variations on the TAVAREC trial samples.
View Article and Find Full Text PDFPurpose: The purpose of this study is to develop a European Organisation for Research and Treatment of Cancer Quality of Life Group (EORTC QLG) questionnaire that captures the full range of physical, mental, and social health-related quality of life (HRQOL) issues relevant to disease-free cancer survivors. In this phase III study, we pretested the provisional core questionnaire (QLQ-SURV111) and aimed to identify essential and optional scales.
Methods: We pretested the QLQ-SURV111 in 492 cancer survivors from 17 countries with one of 11 cancer diagnoses.